ClinVar Miner

Submissions for variant NM_002755.4(MAP2K1):c.169A>C (p.Lys57Gln) (rs397516790)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000158014 SCV000616537 likely pathogenic Rasopathy 2017-05-09 reviewed by expert panel curation The c.169A>C (p.Lys57Gln) variant in MAP2K1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; Partners LMM GeneDx internal data 26957, 21766; ClinVar SCV000061249.5; SCV000207949.2). This variant was absent from large population studies (PM2; ExAC, Computational prediction tools and conservation analysis suggest that the p.Lys57Gln variant may impact the protein (PP3). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PM2, PP3, PP2.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000037591 SCV000061249 likely pathogenic Cardio-facio-cutaneous syndrome 2016-02-11 criteria provided, single submitter clinical testing proposed classification - variant undergoing re-assessment, contact laboratory
GeneDx RCV000158014 SCV000207949 likely pathogenic Rasopathy 2019-02-14 criteria provided, single submitter clinical testing To our knowledge, this variant has neither been published as a Pathogenic variant, nor has it been reported as a benign polymorphism. The K57Q missense change is considered to be a non-conservative amino acid substitution, as a positively charged residue (Lys) is replaced by a neutral residue (Gln) at a position in the protein that is highly conserved across species and within related proteins. Furthermore, missense changes in nearby codons (F53S and T55P) have previously been reported in association with cardio-facio-cutaneous syndrome and Costello syndrome, respectively, which are other disorders of the RAS/MAPK pathway (Rodriguez - Viciana et al., 2006; Nava et al., 2007). Therefore, K57Q is considered to be a likely pathogenic variant.
Invitae RCV000158014 SCV001568953 uncertain significance Rasopathy 2018-06-24 criteria provided, single submitter clinical testing This sequence change replaces lysine with glutamine at codon 57 of the MAP2K1 protein (p.Lys57Gln). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with MAP2K1-related disease. ClinVar contains an entry for this variant (Variation ID: 40779). Experimental studies have shown that this missense change causes increased downstream phosphorylation of ERK (PMID: 18632602). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.